| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Carter Immunology Center and Department of Microbiology, University of Virginia, Charlottesville, VA 22908
Short-lived protein translation products have been proposed to be the principal substrates that enter the class I MHC processing and presentation pathway. However, the biochemical nature of these substrates is poorly defined. Whether the major processing substrates are misfolded full-length proteins, or alternatively, aberrantly initiated or truncated polypeptides still remains to be addressed. To examine this, we used melanoma in which one-third of wild-type tyrosinase molecules were correctly folded and localized beyond the Golgi, while the remainder were present in the endoplasmic reticulum in an unfolded/misfolded state. Increasing the efficiency of tyrosinase folding using chemical chaperones led to a reduction in the level of substrate available to the proteasome and decreased the expression of a tyrosinase-derived epitope. Conversely, in transfectants expressing tyrosinase mutants that are completely misfolded, both proteasome substrate and epitope presentation were significantly enhanced. Proteasome substrate availability was a consequence of misfolding and not simply due to retention in the endoplasmic reticulum. Thus, the extent of folding/misfolding of a full-length protein is an important determinant of the level of epitope presentation.
This article has been cited by other articles:
|
|
 |
|
  A. Goldwich, S. S. C. Hahn, S. Schreiber, S. Meier, E. Kampgen, R. Wagner, M. B. Lutz, and U. Schubert Targeting HIV-1 Gag into the Defective Ribosomal Product Pathway Enhances MHC Class I Antigen Presentation and CD8+ T Cell Activation J. Immunol., January 1, 2008; 180(1): 372 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Figueredo, M. P. Limberis, and J. M. Wilson Prediction of Cellular Immune Responses against CFTR in Patients with Cystic Fibrosis after Gene Therapy Am. J. Respir. Cell Mol. Biol., May 1, 2007; 36(5): 529 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tellam, M. H. Fogg, M. Rist, G. Connolly, D. Tscharke, N. Webb, L. Heslop, F. Wang, and R. Khanna Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes J. Exp. Med., March 19, 2007; 204(3): 525 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Altrich-VanLith, M. Ostankovitch, J. M. Polefrone, C. A. Mosse, J. Shabanowitz, D. F. Hunt, and V. H. Engelhard Processing of a Class I-Restricted Epitope from Tyrosinase Requires Peptide N-Glycanase and the Cooperative Action of Endoplasmic Reticulum Aminopeptidase 1 and Cytosolic Proteases J. Immunol., October 15, 2006; 177(8): 5440 - 5450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-B. Qian, E. Reits, J. Neefjes, J. M. Deslich, J. R. Bennink, and J. W. Yewdell Tight Linkage between Translation and MHC Class I Peptide Ligand Generation Implies Specialized Antigen Processing for Defective Ribosomal Products J. Immunol., July 1, 2006; 177(1): 227 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Caron, R. Charbonneau, G. Huppe, S. Brochu, and C. Perreault The structure and location of SIMP/STT3B account for its prominent imprint on the MHC I immunopeptidome Int. Immunol., December 1, 2005; 17(12): 1583 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Goldberg, S. M. Bartido, J. P. Gardner, J. A. Guevara-Patino, S. C. Montgomery, M.-A. Perales, M. F. Maughan, J. Dempsey, G. P. Donovan, W. C. Olson, et al. Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles Clin. Cancer Res., November 15, 2005; 11(22): 8114 - 8121. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
